Cyclin E1 molecular glue degraders (MGDs) represent a potential novel therapeutic approach by directly and selectively targeting a frequently amplified non-enzymatic driver oncogene relevant in ...
Asieris Pharmaceuticals Co. Ltd. has identified compounds acting as inhibitors of CDK1/cyclin A2, CDK2/cyclin E1, CDK4/cyclin D1 and CDK6/cyclin D1 reported to be useful for the treatment of breast ...
Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy ...
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...
(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), Monday announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial evaluating azenosertib in Cyclin E1+ ...
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results